VIE News and Press, Viela Bio Inc. From 09/11/20

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 08/7/2020. Please visit our Tracking Ole Andreas Halvorsen&...

GAITHERSBURG, Md., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today announced that four abstracts have been accepte...

The following slide deck was published by Viela Bio, Inc. in conjunction with their 2020 Q2 earnings Read more ...

Viela Bio, Inc. (VIE) Q2 2020 Earnings Conference Call August 12, 2020 17:00 ET Company Participants Mitchell Chan - Chief Financial Officer Bing Yao - Chairman and Chief Executive Officer Jörn Drappa - Chief Medical Officer and Head, R&D Bill Ragatz - Vice President a...

Image source: The Motley Fool. Viela Bio Inc   (NASDAQ: VIE) Q2 2020 Earnings Call Aug 12, 2020 , 5:00 p.m. ET Operator Continue reading

VIELA BIO (NASDAQ: VIE ) : Q2 GAAP EPS of -$0.74 beats by $0.32 . More news on: Viela Bio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

GAITHERSBURG, Md., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today reported financial results and provided program ...

GAITHERSBURG, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today announced it will host a webcast and conference ...

Biotech  has outpaced nearly every other sector this year in growth. While the S&P 500 was down 3.6% for the year as of Wednesday, the NASDAQ Biotechnology Index (NBI) is up 10.5% in 2020. That growth carries an enormous amount of risk, however, as many biotech companies aren't mak...

Viela Bio Wins FDA Approval for Autoimmune Treatment Viela Bio ( VIE ) reported that the FDA has given its nod for Uplizna or inebilizumab-cdon for treating adult patients suffering from neuromyelitis optica spectrum disorder who are anti-AQP4 antibody positive. It is estimated that near...